Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lisanne E N Manson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Frontiers in Pharmacology|October 19, 2020
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG GuidelinesLisanne E N Manson, Jesse J Swen, Henk-Jan Guchelaar
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact AnalysisLisanne E N Manson, Wilbert B van den Hout, Henk-Jan Guchelaar
Frontiers in Pharmacology|December 8, 2022
Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactionsLisanne E N Manson, Patricia C Y Chan, Stefan Böhringer, et al.
Lancet (London, England)|June 3, 2023
The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors' replyJesse J Swen, Lisanne E N Manson, Stefan Böhringer, et al.
Drug Safety|June 14, 2025
Reporting Adverse Drug Events: A Comparison of an Online Patient Tool Versus Telephone-Based Monitoring in Community Pharmacy Patients in the NetherlandsHenok D Habtemariam, Henk-Jan Guchelaar, Lisanne E N Manson, et al.
The Pharmacogenomics Journal|February 18, 2025
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening - a case-control studyLisanne E N Manson, Jacqueline D H Anholts, Jos J M Drabbels, et al.
Frontiers in Genetics|November 1, 2023
Repurposing HLA genotype data of renal transplant patients to prevent severe drug hypersensitivity reactionsLisanne E N Manson, Sander J Delwig, Jos J M Drabbels, et al.
European Journal of Human Genetics : EJHG|April 3, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugsLisanne E N Manson, Marga Nijenhuis, Bianca Soree, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE StudyHenk-Jan Guchelaar, Cathelijne H van der Wouden, Lisanne E N Manson, et al.
Eclinicalmedicine|January 8, 2026
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE studyVasileios Fragoulakis, Jesse J Swen, Margarita-Ioanna Koufaki, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Frontiers in Pharmacology|October 19, 2020
Diagnostic Test Criteria for HLA Genotyping to Prevent Drug Hypersensitivity Reactions: A Systematic Review of Actionable HLA Recommendations in CPIC and DPWG GuidelinesLisanne E N Manson, Jesse J Swen, Henk-Jan Guchelaar
Pharmaceuticals (Basel, Switzerland)|January 21, 2022
Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact AnalysisLisanne E N Manson, Wilbert B van den Hout, Henk-Jan Guchelaar
Frontiers in Pharmacology|December 8, 2022
Genotyping for HLA risk alleles versus patch tests to diagnose anti-seizure medication induced cutaneous adverse drug reactionsLisanne E N Manson, Patricia C Y Chan, Stefan Böhringer, et al.
Lancet (London, England)|June 3, 2023
The PREPARE study: benefits of pharmacogenetic testing are unclear - Authors' replyJesse J Swen, Lisanne E N Manson, Stefan Böhringer, et al.
Drug Safety|June 14, 2025
Reporting Adverse Drug Events: A Comparison of an Online Patient Tool Versus Telephone-Based Monitoring in Community Pharmacy Patients in the NetherlandsHenok D Habtemariam, Henk-Jan Guchelaar, Lisanne E N Manson, et al.
The Pharmacogenomics Journal|February 18, 2025
The association between the number of HLA risk alleles and drug allergy and its implications for HLA screening - a case-control studyLisanne E N Manson, Jacqueline D H Anholts, Jos J M Drabbels, et al.
Frontiers in Genetics|November 1, 2023
Repurposing HLA genotype data of renal transplant patients to prevent severe drug hypersensitivity reactionsLisanne E N Manson, Sander J Delwig, Jos J M Drabbels, et al.
European Journal of Human Genetics : EJHG|April 3, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of CYP2C9, HLA-A and HLA-B with anti-epileptic drugsLisanne E N Manson, Marga Nijenhuis, Bianca Soree, et al.
Clinical Pharmacology and Therapeutics|June 24, 2025
Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE StudyHenk-Jan Guchelaar, Cathelijne H van der Wouden, Lisanne E N Manson, et al.
Eclinicalmedicine|January 8, 2026
Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE studyVasileios Fragoulakis, Jesse J Swen, Margarita-Ioanna Koufaki, et al.
Pageof 1